Company Overview - X4 Pharmaceuticals focuses on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs [2] - The company has developed mavorixafor, an orally available CXCR4 antagonist, which is commercially available in the U.S. as XOLREMDI® for its first indication [2] - X4 is conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders [2] - The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia [2] - X4 Pharmaceuticals is headquartered in Boston, Massachusetts [2] Upcoming Events - The management team of X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026, at 10:00 a.m. ET in Miami, FL [1] - A link to the live and archived webcast will be available on X4 Pharmaceuticals' website under the Investors section: Events and Presentations [1]